Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
88.98
+1.73 (1.98%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Spyre Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 162.01 | 85.72 | 89.42 | 188.89 | 34.86 | 15.14 |
Short-Term Investments | 983.34 | 670.81 | 513.67 | 150.38 | 20.85 | 77.99 |
Cash & Short-Term Investments | 1,145 | 756.53 | 603.09 | 339.28 | 55.71 | 93.13 |
Cash Growth | 117.51% | 25.44% | 77.76% | 509.00% | -40.18% | -36.33% |
Other Receivables | 8.8 | 3 | - | - | 0.38 | 0.82 |
Receivables | 8.8 | 3 | - | - | 0.38 | 0.82 |
Prepaid Expenses | 18.86 | 18.25 | 5.39 | 2.25 | 6.17 | 4.95 |
Total Current Assets | 1,173 | 777.78 | 608.47 | 341.53 | 62.26 | 98.89 |
Property, Plant & Equipment | - | - | - | - | 7.25 | 9.15 |
Other Long-Term Assets | - | - | 0.01 | 0.33 | 1.64 | 1.88 |
Total Assets | 1,173 | 777.78 | 608.48 | 341.86 | 71.14 | 109.93 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 5.72 | 8.9 | 0.67 | 0.9 | 0.68 | 3.32 |
Accrued Expenses | 26.18 | 26.77 | 27.31 | 29.2 | 12.82 | 13.25 |
Current Portion of Leases | - | - | - | - | 0.64 | 0.85 |
Current Unearned Revenue | - | - | - | - | 0.52 | 2.36 |
Other Current Liabilities | 31.4 | 23.01 | 26.08 | 1.88 | - | 0.37 |
Total Current Liabilities | 63.3 | 58.69 | 54.06 | 31.98 | 14.66 | 20.14 |
Long-Term Leases | - | - | - | - | 4 | 4.62 |
Long-Term Unearned Revenue | - | - | - | - | 2.18 | 1.22 |
Other Long-Term Liabilities | 8.56 | 3.86 | 36.62 | 125.87 | - | - |
Total Liabilities | 71.86 | 62.55 | 90.68 | 157.84 | 20.84 | 25.99 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 2,190 | 1,686 | 1,334 | 763.19 | 475.97 | 425.77 |
Retained Earnings | -1,233 | -1,128 | -972.43 | -764.41 | -425.62 | -341.81 |
Comprehensive Income & Other | -2.4 | 0.87 | 0.18 | 0.3 | -0.05 | -0.02 |
Total Common Equity | 954.72 | 559.42 | 361.98 | -0.91 | 50.31 | 83.94 |
Shareholders' Equity | 1,101 | 715.24 | 517.8 | 184.02 | 50.31 | 83.94 |
Total Liabilities & Equity | 1,173 | 777.78 | 608.48 | 341.86 | 71.14 | 109.93 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | - | - | - | 4.65 | 5.48 |
Net Cash (Debt) | 1,145 | 756.53 | 603.09 | 339.28 | 51.07 | 87.65 |
Net Cash Growth | 117.51% | 25.44% | 77.76% | 564.39% | -41.74% | -37.73% |
Net Cash Per Share | 15.33 | 11.81 | 12.82 | 49.19 | 15.15 | 33.33 |
Filing Date Shares Outstanding | 88.17 | 78.54 | 60.28 | 36.15 | 2.62 | 1.97 |
Total Common Shares Outstanding | 88.06 | 78.19 | 60.26 | 36.06 | 2.61 | 1.97 |
Working Capital | 1,110 | 719.1 | 554.41 | 309.55 | 47.6 | 78.75 |
Book Value Per Share | 10.84 | 7.15 | 6.01 | -0.03 | 19.24 | 42.52 |
Tangible Book Value | 954.72 | 559.42 | 361.98 | -0.91 | 50.31 | 83.94 |
Tangible Book Value Per Share | 10.84 | 7.15 | 6.01 | -0.03 | 19.24 | 42.52 |
Machinery | - | - | - | - | 2.85 | 2.82 |
Leasehold Improvements | - | - | - | - | 4.39 | 4.39 |